Iron accumulation in the heart of a patient with primary hemochromatosis type I (homozygous C282Y mutation of the HFE gene)
Authors:
- M.H.E. LaouarMLM.H.E. Laouar
- R. V. PonomarevRPR. V. Ponomarev
- E. S. NeronovaENE. S. Neronova
- N. T. TynybekovaNTN. T. Tynybekova
- I. V. TremzinaITI. V. Tremzina
- M. M. MalaginaMMM. M. Malagina
- A. B. LeonovaALA. B. Leonova
- V. А. BaranovaVBV. А. Baranova
- E. O. SaakyantsESE. O. Saakyants
- P. A. OvcharenkoPOP. A. Ovcharenko
- 28 August 2026
- journal article
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (6) , 476-482
Abstract
Primary hemochromatosis results from pathogenic variants in several genes that can lead to increased iron stores in the body, with excess iron deposited in various organs including the liver, pancreas, and heart. Primary hemochromatosis is associated with homozygosity for the HFE p.Cys282Tyr mutation in 80% of cases. However, rare cases of hemochromatosis (nonHFE hemochromatosis) can be caused by pathogenic variants in other genes (such as HJV, HAMP, TFR2, and SLC40A1). Deposition of excess iron in parenchymal tissues leads to cellular dysfunction and clinical manifestations of the disease. The most commonly aff ected organs are the liver, pancreas, joints, skin, pituitary gland, and heart. Iron-overload cardiomyopathy is systolic or diastolic dysfunction of the heart caused by excess iron deposition, resulting in chronic heart failure. The gold standard for diagnosing primary hemochromatosis is genetic testing, which should be performed in all patients suspected of having this pathology after excluding secondary causes of iron overload. The mainstay of hemochromatosis therapy is therapeutic phlebotomy and iron chelation. The article presents a clinical case of a patient with primary hemochromatosis and a history of very high serum ferritin levels, which led to iron accumulation in the heart.Keywords
This publication has 16 references indexed in Scilit:
- HFE genotypes, haemochromatosis diagnosis and clinical outcomes at age 80 years: a prospective cohort study in the UK BiobankBMJ Open, 2024
- Diagnosis and Management of Hereditary HemochromatosisJAMA, 2022
- What Is Hereditary Hemochromatosis?2022
- EASL Clinical Practice Guidelines on haemochromatosisJournal of Hepatology, 2022
- Comparison of Inline R2* MRI versus FerriScan for liver iron quantification in patients on chelation therapy for iron overload: preliminary resultsEuropean Radiology, 2021
- Keeping heart homeostasis in check through the balance of iron metabolismActa Physiologica, 2019
- Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK BiobankBMJ, 2019
- Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac functionProceedings of the National Academy of Sciences, 2015
- Iron-Overload Cardiomyopathy: Pathophysiology, Diagnosis, and TreatmentJournal of Cardiac Failure, 2010
- A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE -Related Hereditary HemochromatosisHepatology, 2010